Patents Issued in July 30, 2020
-
Publication number: 20200239832Abstract: The present invention relates to the production of o-aminobenzoic acid from fermentable substrates using microbial cells and alkali-containing bases during fermentationType: ApplicationFiled: October 12, 2018Publication date: July 30, 2020Inventors: Gernot JÄGER, Wolf KLOECKNER, Swantje BEHNKEN, Simon KLAFFL, Jamaleddine SASSI
-
Publication number: 20200239833Abstract: Methods of using magnetic display cells to replace secondary antibodies and magnetic beads in any cell manipulation methods. Cells displaying ligands for target cells are magnetized, and then used to bind the target cells. The complex can then be collected in a magnetic field, and thereby manipulated according to the application needs.Type: ApplicationFiled: August 1, 2018Publication date: July 30, 2020Inventor: Glauco SOUZA
-
Publication number: 20200239834Abstract: Provided is a large-scale cell culture system for producing products without harming animals. Also provided is a method for making meat products using this cell culture system. Further provided is a method for making personal care products using this cell culture system, as well as a method for making nutritional supplements using this cell culture system.Type: ApplicationFiled: April 16, 2020Publication date: July 30, 2020Inventors: Gabor FORGACS, Niyati GUPTA
-
Publication number: 20200239835Abstract: A method for isolating and/or culturing cambium stem cells of panax ginseng is disclosed. The method comprises a step of treating tissues containing panax ginseng cambium with a compound of formula I. The present application further relates to cambium stem cells of panax ginseng obtained according to the method and use of such cambium stem cells in preparing a product for a suspension culture of panax ginseng. The method for isolating and/or culturing cambium stem cells of panax ginseng according to the present application can effectively separate the cambium stem cells of the panax ginseng which have unlimited cytodieresis ability and strong anti-adversity ability, can provide a basis for ultra-large volume liquid culture, which can significantly reduce production costs.Type: ApplicationFiled: March 8, 2019Publication date: July 30, 2020Inventors: Dong Wu, Chensheng Dai, Lili Cheng, Huaide Chen, Minxian Liu, Lili Hou, Zhuohe Jiang, Yujia Liu, Yuanjian Ling
-
Publication number: 20200239836Abstract: Biological products are disclosed that have improved qualities relative to those that are currently available. Disclosed are compositions and methods for modulating cellular physiology and pathological processing using compositions that are derived from various placenta/villous chorion tissue.Type: ApplicationFiled: March 14, 2017Publication date: July 30, 2020Inventor: Scott A. Washburn
-
Publication number: 20200239837Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.Type: ApplicationFiled: February 12, 2020Publication date: July 30, 2020Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
-
Publication number: 20200239838Abstract: The invention provides a method of differentiating human pluripotent stem cells to ectodermal cell by treating human pluripotent stem cells, which are dissociated single cells, and inducing differentiation to ectodermal cells under conditions where a ROCK (Rho-kinase) inhibitor is present in a culture medium in contact with the cells after dissociation of the human pluripotent stem cells.Type: ApplicationFiled: April 17, 2020Publication date: July 30, 2020Applicant: RIKENInventors: Yoshiki Sasai (deceased), Kiichi Watanabe
-
Publication number: 20200239839Abstract: The present invention provides a product comprising plated human hepatocytes on a surface and at least some of the plated hepatocytes are in one or more hepatocyte clusters on feeder cells, which are attached to the surface. A method of preparing plated human hepatocytes is also provided. The preparation method comprises applying human hepatocytes to a surface in the presence of feeder cells, co-culturing the applied hepatocytes with the feeder cells, and forming one or more hepatocyte clusters by the co-cultured hepatocytes on the feeder cells, which are attached to the surface. The plated hepatocytes may be used for various purposes, including the preparation of a hepatitis B virus (HBV) infected hepatocyte culture model and drug testing.Type: ApplicationFiled: September 22, 2018Publication date: July 30, 2020Applicant: LifeNet HealthInventors: Jung Bok LEE, Angela Murchison, Edward LeCluyse, Jingsong Chen
-
Publication number: 20200239840Abstract: The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.Type: ApplicationFiled: March 13, 2020Publication date: July 30, 2020Applicant: Wisconsin Alumni Research FoundationInventors: James A. Thomson, Junying Yu
-
Publication number: 20200239841Abstract: The present disclosure relates to methods and compositions for generating topographically organized tissues in vitro, for the resulting cultured tissue and components thereof, and for uses of such cultured tissue and its components in drug discovery, toxicology studies, and therapy.Type: ApplicationFiled: January 27, 2020Publication date: July 30, 2020Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Gustav Cederquist
-
Publication number: 20200239842Abstract: Preparation and expansion methods for human pluripotent stem cell-derived human retinal pigment epithelial cells are provided. The preparation method includes the following steps: collecting 3D-PRE spheroids derived from human pluripotent stem cells, performing mechanical separation to remove non-RPE cells and clusters which are non-pigmented and retain a pigmented RPE cell sheet, enzymatically digesting the pigmented RPE cell sheet to obtain an RPE single cell suspension, and thereby the human pluripotent stem cell-derived human retinal pigment epithelial cells are obtained. The expansion method includes centrifuging the RPE single cell suspension and removing a supernatant, resuspending in an RPE cell medium and seeding into a cell culture container precoated with extracellular matrix to allow primary culture, and subculturing the cells after cells spread out.Type: ApplicationFiled: April 28, 2018Publication date: July 30, 2020Applicant: ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITYInventors: Xiufeng ZHONG, Jian GE, Shengxu LIU, Fuhua PENG
-
Publication number: 20200239843Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.Type: ApplicationFiled: October 1, 2018Publication date: July 30, 2020Applicants: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., EBERHARD KARLS UNIVERSITÄT TÜBINGENInventors: Peter LOSKILL, Christopher PROBST, Stefan LIEBAU, Kevin ACHBERGER, Jasmin HADERSPECK
-
Publication number: 20200239844Abstract: Disclosed herein are various embodiments relating to methods of producing iMGLs, for example, from pluripoteiit stem cells (PSCs), methods of using iMGLs, and compositions of iMGLs. Also disclosed herein are methods to study various neurological disorders, such as for studying Alzheimer's disease. In addition, disclosed herein are methods of investigating genotypic and phenotypic effects of microglia cells in various physiological and pathological environments in the CNS and brain.Type: ApplicationFiled: February 26, 2018Publication date: July 30, 2020Inventors: Mathew BLURTON-JONES, Edsel ABUD, Wayne POON
-
Publication number: 20200239845Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.Type: ApplicationFiled: April 14, 2020Publication date: July 30, 2020Inventors: Sirac DILBER, Evren ALICI
-
Publication number: 20200239846Abstract: A process for the preparation of chondrocyte cell suspension and its use in defect site of knee or ankle or shoulder or wrist or elbow or hip of subject.Type: ApplicationFiled: November 30, 2017Publication date: July 30, 2020Inventors: Satyen SANGHAVI, Vinayak KEDAGE
-
Publication number: 20200239847Abstract: The disclosure provides a method of preparing a pluripotent stem cell suitable for differentiating into a cardiomyocyte comprising (1) culturing at least one pluripotent stem cell on a low cell adhesion substrate to generate a dome-like colony; and (2) collecting a cell from the dome-like colony. The disclosure also provides a method of preparing a population of cardiomyocytes comprising inducing myocardial differentiation of a population of pluripotent stem cells prepared by the method described above.Type: ApplicationFiled: October 17, 2018Publication date: July 30, 2020Applicant: Kyoto UniversityInventors: Li Liu, Leqian Yu, Junjun Li
-
Publication number: 20200239848Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.Type: ApplicationFiled: April 13, 2020Publication date: July 30, 2020Inventors: Gordon Keller, April M. Craft, Nicole C. Dubois
-
Publication number: 20200239849Abstract: A method for purifying and enriching mesenchymal stem cells (MSCs) simply and efficiently. Separation of cells expressing CD73 protein on the surface from fresh tissue isolated from a living body allows purification and enrichment of MSCs easily and efficiently. MSCs may be selectively isolated with a single antibody before culturing to establish a culture system of mesenchymal stem cells that enhances the engraftment efficiency in the transplanted site.Type: ApplicationFiled: May 11, 2018Publication date: July 30, 2020Inventors: Chihiro AKAZAWA, Eriko Grace SUTO, Yo MABUCHI
-
Publication number: 20200239850Abstract: The present invention provides human bone-marrow cells enriched with functional mitochondria, methods for their production, and therapeutic methods utilizing such cells.Type: ApplicationFiled: March 24, 2020Publication date: July 30, 2020Inventors: Natalie YIVGI-OHANA, Uriel HALAVEE
-
Publication number: 20200239851Abstract: Disclosed is a nanofiber-based long-term primary hepatocyte culture system and a culture method, wherein the primary hepatocyte culture system has an advantage that it can culture cells in three-dimensions in vitro to maintain the original physiological activity of low proliferative primary hepatocytes for a long time by co-culturing indirectly by separating primary hepatocytes and hepatic non-parenchymal cells with a support consisting of nanofibers therebetween without direct co-culture.Type: ApplicationFiled: September 21, 2018Publication date: July 30, 2020Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Jong-Young KWAK, Min Gyu SONG, So Hee KIM, Min Ho CHOI
-
Publication number: 20200239852Abstract: A method of cell culture comprising providing cells in a cell culture medium to start a cell culture process, and, maintaining at least one metabolite selected from 3-(4-hydroxyphenyl)lactate, 4-hydroxyphenylpyruvate, phenyllactate, indolelactate, indolecarboxylic acid, homocysteine, 2-hydroxybutyric acid, isovalerate and formate below a concentration C1 in the cell culture medium, wherein C1 is 3 mM and/or (ii) maintaining at least one amino acid selected from phenylalanine, tyrosine, tryptophan, methionine, leucine, serine, threonine and glycine below a concentration C2 in the cell culture medium, wherein C2 is 2 mM.Type: ApplicationFiled: December 20, 2019Publication date: July 30, 2020Applicant: Pfizer Inc.Inventors: Gregory Walter Hiller, Bhanu Chandra Mulukutla
-
Publication number: 20200239853Abstract: Provided are stem cells-induced Serotoli-like cells, methods of preparing the same, and uses thereof. Sertoli-like cells according to one embodiment can be differentiated from embryonic stem cells with excellent proliferative capacity, and thus, can be obtained in large quantities. Also, since the Sertoli-like cells secrete immunosuppressive substances and form immune privilege and induce anti-inflammatory functions, they can be used for development of the cell therapeutic agent.Type: ApplicationFiled: March 6, 2020Publication date: July 30, 2020Applicant: CHA University Industry-Academic Cooperation FoundationInventors: Dong Ryul LEE, Dong Won Seol
-
Publication number: 20200239854Abstract: Provided are a method capable of evaluating adherent cells under an environment similar to an in vivo environment by a culture method similar to a two-dimensional culture, and applications thereof. An adherent cell culture method uses, as a culture chamber (10), a chamber in which two or more culture spaces each having an equivalent diameter (D) that is 1 to 5 times the diameter of a desired spheroid and each having a height (H) that is 0.3 to 5 times the equivalent diameter are arranged and a surface of each of the culture spaces has a water contact angle of 45 degrees or less. Spheroids of adherent cells are cultured in the respective culture spaces (11) arranged in the culture chamber (10).Type: ApplicationFiled: April 13, 2020Publication date: July 30, 2020Inventors: Satoru Ayano, Masaya Hosoda, Yoko Ejiri, Go Tazaki
-
Publication number: 20200239855Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 28, 2019Publication date: July 30, 2020Inventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Publication number: 20200239856Abstract: The present invention aims to provide a method for producing a cartilage tissue, which enables production of a cartilage tissue having an appropriate thickness, form, and mechanical strength, and a cartilage tissue produced by the method for producing a cartilage tissue. Provided is a method for producing a cartilage tissue including a step of seeding a collagenase-treated cartilage tissue piece in the form of a block 50 to 1,000 ?m on a side onto a porous substrate composed of a bioabsorbable material.Type: ApplicationFiled: November 29, 2018Publication date: July 30, 2020Inventors: William J. LANDIS, Robin CHILDS, Narihiko HIRANO, Tomokazu FUKUDA
-
Publication number: 20200239857Abstract: Disclosed is a skin-on-a-chip, which more closely resembles real skin by simulating the repetition of contraction and relaxation due to stretching of skin cells, by embedding a permanent magnet in the skin-on-a-chip. The skin-on-a-chip includes a connector that causes a linear motion in the skin cells of the chip when driven by a linear drive device outside the chip, which provides forward and backward movement, to thereby simulate contraction and relaxation of skin.Type: ApplicationFiled: December 29, 2017Publication date: July 30, 2020Inventors: Gun Yong SUNG, Ho Yeong LIM, Hyun Jeong SONG, Sungsu PARK
-
Publication number: 20200239858Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.Type: ApplicationFiled: September 4, 2019Publication date: July 30, 2020Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
-
Publication number: 20200239859Abstract: The invention generally concerns the production of defective Adenovirus helper viruses for producing a recombinant adeno-associated virus (rAAV), wherein the Adenovirus helper virus contains at least one mutation selected from (a) an inactivating mutation in the transcription unit coding for the L4-100K protein; (b) an inactivating mutation in the transcription unit coding for the L1-52/55K protein; (c) an inactivating mutation in the transcription unit coding for the preterminal protein (pTP); (d) a mutation in the L4-100K protein in order to render it temperature-sensitive (ts); (e) a mutation in the hexon protein in order to render it temperature-sensitive (ts); and/or (f) a mutation in the L4-00K protein and a mutation in the hexon protein in order to render it temperature-sensitive (ts).Type: ApplicationFiled: October 12, 2018Publication date: July 30, 2020Inventors: Markus HÖRER, Stefan KOCHANEK, Caroline HAUSER, Alexandra KRÜGER-HAAG
-
Publication number: 20200239860Abstract: Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.Type: ApplicationFiled: January 29, 2020Publication date: July 30, 2020Inventors: Stephen Erickson, Jose S. Gil, Minh Mindy Bao Nguyen, Dwight L. Anderson
-
Publication number: 20200239861Abstract: A method of preparing isolated microsomes comprising an irreversibly inhibited cytochrome P450 (CYP450). Isolated microsomes are characterized in that a cytochrome P450 thereof is irreversibly inhibited by a non-reversible inhibitor. The isolated microsomes according to the invention may be used in a method of phenotyping enzymatic reactions of a drug candidate.Type: ApplicationFiled: April 17, 2020Publication date: July 30, 2020Inventors: Fabrice CARADEC, Yannick Parmentier, Corinne Pothier
-
Publication number: 20200239862Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein.Type: ApplicationFiled: September 28, 2018Publication date: July 30, 2020Applicant: BETHPHAGEN INC.Inventors: Tae Hwan KWAK, Woo Jin PARK
-
Publication number: 20200239863Abstract: Cas9 polypeptides which target RNA and methods of using them are providedType: ApplicationFiled: February 19, 2020Publication date: July 30, 2020Inventors: Eugene Yeo, David A. Nelles, Mark Fang, Ranjan Batra
-
Publication number: 20200239864Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.Type: ApplicationFiled: April 17, 2020Publication date: July 30, 2020Applicant: Precision BioSciences, Inc.Inventors: Derek Jantz, James Jefferson Smith
-
Publication number: 20200239865Abstract: The present invention relates to the technical field of protein engineering, and, in particular, to a xylanase mutant with improved heat tolerance. The present invention artificially introduces two or three unnatural disulfide bridges into xylanase by site-directed mutagenesis and obtains the mutants XynA1 and XynA2 with improved heat tolerance, especially the mutant XynA2 into which three disulfide bridges are introduced, achieving residual enzyme activity of 75% after treatment at 80° C. for 5 min, 72% higher than the residual enzyme activity of the mutant XynA1. The present invention further obtains, by screening, three mutation sites Q51N, H143K, and Q161F that can significantly increase the heat tolerance of mutants, and introduction of the mutation sites into the XynA1 and XynA2 xylanases, whether at a single point or a combination of two points or a combination of three points, can effectively improve the heat tolerance of the mutants.Type: ApplicationFiled: April 19, 2018Publication date: July 30, 2020Applicant: QINGDAO VLAND BIOTECH GROUP CO., LTDInventors: Xiuxiu WU, Chao SHAO, Yijun HUANG
-
Publication number: 20200239866Abstract: Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a cis-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired.Type: ApplicationFiled: February 3, 2020Publication date: July 30, 2020Inventors: Michael Z. LIN, Hokyung CHUNG, Conor JACOBS
-
Publication number: 20200239867Abstract: Variant guinea pig L-asparaginases which are truncated and humanized are described as are fusion proteins containing the L-asparaginase and use of the L-asparaginases in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.Type: ApplicationFiled: August 10, 2018Publication date: July 30, 2020Inventors: Arnon Lavie, Hien-An Nguyen, Amanda Schalk
-
Publication number: 20200239868Abstract: The present disclosure relates to the generation of an activated platelet product in which one or more of the presence or absence of clots, the timing of clot formation (if present), and/or the mechanical strength of clots (if present) is controlled by the presence or concentration of calcium ions during the activation process. In certain embodiments, the calcium ion concentration is controlled in the presence of pulsed electric fields or a chemical activator (e.g., thrombin) as part of the activation process.Type: ApplicationFiled: April 16, 2020Publication date: July 30, 2020Inventors: Vasile Bogdan Neculaes, Andrew Soliz Torres, Steve Lambert Klopman
-
Publication number: 20200239869Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner. In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by using multiple ion pairing agents in the same mobile phase system. Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.Type: ApplicationFiled: August 17, 2018Publication date: July 30, 2020Applicant: ModernaTX, Inc.Inventors: William Issa, Meredith Packer
-
Publication number: 20200239870Abstract: The present invention relates to the field of nucleic acid purification. In particular, it relates to methods and tools for purifying nucleic acids in a sample; which are compatible with high-throughput sequencing and diagnosis. The inventors have shown that nucleic acid binding proteins recruited to polymerized tubulin (i.e. microtubules) could, subsequently, be isolated from cell lysates. Surprisingly, it has now been found that the amount of recovered nucleic acid found in these microtubule pellets increases dramatically in the presence of nucleic acid-trapping proteins comprising a nucleic acid-binding moiety and a polymerized tubulin-binding moiety, by comparison to proteins devoid of the nucleic acid-binding moiety; and that the recovery of the purified nucleic acids was itself particularly efficient. This purification method is particularly amenable to high-throughput sequencing and/or in the context of a diagnosis method for identifying or comparing the amount of nucleic acids in a set of samples.Type: ApplicationFiled: July 27, 2018Publication date: July 30, 2020Inventors: David PASTRE, Bénédicte DESFORGES, Alexandre MAUCUER
-
Publication number: 20200239871Abstract: The present invention relates to a method for selectively depleting animal nucleic acids from non-animal nucleic acids in a sample, which comprises animal cells and at least one further type of cells, selected from microbial cells and plant cells or a combination thereof, to a lysis solution A to be used in and to a kit to carry out said method as well as to the use of a particular silica membrane as both, a filtration matrix for separating essentially intact microbial and/or plant cells from lysed animal cells and an adsorption matrix for nucleic acids, in particular in a method according to the present invention.Type: ApplicationFiled: April 14, 2020Publication date: July 30, 2020Inventors: Johann KUBICEK, Thorsten SINGER, Antje-Katrin SANDER, Eva HÄNSSLER, Dominic O'NEIL
-
Publication number: 20200239872Abstract: Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.Type: ApplicationFiled: March 13, 2018Publication date: July 30, 2020Applicant: Duke UniversityInventors: Thomas F. TEDDER, Evgueni KOUNTIKOV
-
Publication number: 20200239873Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.Type: ApplicationFiled: April 2, 2020Publication date: July 30, 2020Inventors: Zach SERBER, Erik Jedediah Dean, Shawn Manchester, Katherine Gora, Michael Flashman, Erin Shellman, Aaron Kimball, Shawn Szyjka, Barbara Frewen, Thomas Treynor, Kenneth S. Bruno
-
Publication number: 20200239874Abstract: The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.Type: ApplicationFiled: August 28, 2019Publication date: July 30, 2020Inventors: Tarjei Sigurd Mikkelsen, Eswar Prasad Ramachandran Iyer, Andrew Kohlway, Luigi Jhon Alvarado Martinez, Katherine Pfeiffer, Andrew D. Price
-
Publication number: 20200239875Abstract: The invention provides methods for controlling the density of different molecular species on the surface of a solid support. A first mixture of different molecular species is attached to a solid support under conditions to attach each species at a desired density, thereby producing a derivatized support having attached capture molecules. The derivatized support is treated with a second mixture of different molecular species, wherein different molecular species in the second mixture bind specifically to the different capture molecules attached to the solid support. One or more of the capture molecules can be reversibly modified such that the capture molecules have a different activity before and after the second mixture of molecular species are attached. In particular embodiments, the different molecular species are nucleic acids that are reversibly modified to have different activity in an amplification reaction.Type: ApplicationFiled: February 10, 2020Publication date: July 30, 2020Inventors: Andrea Sabot, Roberto Rigatti, Min-Jui Richard Shen
-
Publication number: 20200239876Abstract: The present invention provides new methods and kits to improve the efficiency of ligation reactions, in particular in molecular biology applications, such as the next generation sequencing (NGS) library construction methods. In next-generation sequencing methods, the ligation step is critical in adding sequencing platform-specific adapters to the DNA fragments that are to be sequenced. Said improvement is achieved by the addition of single- or double-stranded DNA-binding proteins in the ligation step.Type: ApplicationFiled: March 13, 2020Publication date: July 30, 2020Inventors: Katja Heitz, Nan Fang
-
Publication number: 20200239877Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.Type: ApplicationFiled: April 6, 2020Publication date: July 30, 2020Inventors: Wolfgang HINZ, John LEAMON, David LIGHT, Jonathan M. ROTHBERG
-
Publication number: 20200239878Abstract: Described herein are methods and compositions that provide highly efficient nucleic acid amplification. In some embodiments, this allows a 3-fold or greater increase of amplification product for each amplification cycle and therefore increased sensitivity and speed over conventional PCR. Modified bases can be employed in primers to provide this base-3 or greater amplification with satisfactory PCR cycle times, which are improved, as compared to those observed in the absence of modified bases.Type: ApplicationFiled: October 29, 2019Publication date: July 30, 2020Applicant: CepheidInventor: Russell Higuchi
-
Publication number: 20200239879Abstract: Compositions and methods for conditionally regulating activities of CRISPR-Cas systems. In some embodiments, the methods comprise providing an inactive guide RNA comprising a regulatory domain bound by a lock nucleic acid different from the guide RNA; and displacing the lock nuclei acid from the regulatory domain by a trigger nucleic acid, thereby activating the guide RNA, wherein the activated guide RNA forms a complex with a Cas enzyme.Type: ApplicationFiled: January 29, 2020Publication date: July 30, 2020Inventors: Amit Choudhary, Kurt Cox, Hari Subramanian, Elisa Franco
-
Publication number: 20200239880Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.Type: ApplicationFiled: February 14, 2020Publication date: July 30, 2020Inventors: Jeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
-
Publication number: 20200239881Abstract: The present invention provides morpholino modified oligomeric compounds having at least one monomer subunit having Formula III, compounds having Formula I useful for making certain of the morpholino modified oligomeric compounds and methods of using the oligomeric compounds. In certain embodiments, the oligomeric compounds provided herein provide for an improved toxicity profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: March 9, 2018Publication date: July 30, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth